Aceklofenak – dlaczego warto wypróbować w chorobie zwyrodnieniowej stawów? Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
wrz 30, 2012
Słowa kluczowe:
aceklofenak, choroba zwyrodnieniowa, skuteczność, bezpieczeństwo
##plugins.themes.bootstrap3.article.main##
Abstrakt
Choroba zwyrodnieniowa stawów (ChZS) jest jednym z najczęściej występujących schorzeń układu ruchu. Typowe objawy choroby zwyrodnieniowej to ból i ograniczenie ruchomości w zajętym stawie. Aceklofenak jest zaliczany do grupy selektywnych niesteroidowych leków przeciwzapalnych (NLPZ) o udowodnionej skuteczności w chorobie zwyrodnieniowej i dobrym profilu bezpieczeństwa. Dodatkowe cechy kliniczne (szybki początek działania, potencjalnie dobry wpływ na metabolizm chrząstki stawowej) czynią z aceklofenaku pożądaną opcję terapeutyczną w ChZS.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Rupiński , R. (2012). Aceklofenak – dlaczego warto wypróbować w chorobie zwyrodnieniowej stawów? . Medycyna Faktów , 5(3(16), 25-30. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2451
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Reumatologia. Puszczewicz M. (red.). Medical Tribune Polska, Warszawa 2010.
2. EULAR Textbook of Rheumatic Diseases. Bijlsma J.W.J. (red.). BMJ Group, London 2012.
3. Crema A., Crema F., Parnham M.J. et al.: Effect of food on the bioavailability of aceclofenac tablets in healthy volunteers. Eur. J. Clin. Res. 1995; 7: 155-60.
4. Charakterystyka produktu leczniczego aceklofenak.
5. Jordan K.M., Arden N.K., Doherty M. et al.: EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Ann. Rheum. Dis. 2003; 62: 1145-55.
6. Batlle-Gualda E., Román Ivorra J., Martin-Mola E. et al.: Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind 6-week randomized controlled trial. Osteoarthritis and Cartilage 2007; 15: 900-8.
7. Diaz C., Rodriguez de la Sera A., Geli C. et al.: Efficacy and tolerability of aceclofenac versus diclofenac in the treatment of knee osteoarthritis: a multicentre study. Eur. J. Rheumatol. Inflamm. 1996; 16: 17-22.
8. Perez Busquier M., Calero E., Rodriguez M. et al.: Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. Clin. Rheumatol. 1977; 16: 154-59.
9. Kornasoff D., Frerick H., Bowdler J., Montull E.: Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis. Clin. Rheumatol. 1997; 16: 32-38.
10. Schattenkirchner M., Milachowski K.A.: A double-blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute lob back pain. Clin. Rheumatol. 2003; 22: 127-35.
11. Calin A., Murray F.E.: Aceclofenac: side effects and safety. Eur. J. Rheumatol. Inflamm. 1996; 16: 13-6.
12. Huskisson E.C., Irani M., Murray F.: A large prospective open-label, multicentre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Eur. J. Rheumatol. Inflamm. 2000; 17: 1-7.
13. Peris F., Bird H.A., Serni U. et al.: Treatment compliance and safety of aceclofenac versus standard NSAIDs in patients with common arthritic disorders: a meta-analysis. Eur. J. Rheumatol. Inflamm. 1996; 16: 37-45.
14. Yanagawa A., Endo T., Kusakari K. et al.: Endoscopic evaluation of aceclofenac induced gastroduodenal mucosal damage: a double-blind comparison with sodium diclofenac and placebo. Japan J. Rheumatol. 1998; 8: 249-59.
15. Llorente Melero M.J., Tenias Burillo J.M., Caragoza Marcet A.: Comparative incidence of upper gastrointestinal bleeding associated with individual non-steroidal anti-inflammatory drugs. Rev. Esp. Enferm. Dig. 2002; 94: 7-18.
16. Lanas A., Garcýa-Rodrýguez L.A., Arroyo M.T. et al.: Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal antiinflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731-1738.
17. Kornasoff D., Maisenbacher J., Bowdler J., Raber A.: The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis. Rheumatol. Int. 1996; 15: 225-30.
18. Battle-Gualda E., Figueroa M., Ivorra J., Raber A.: The efficacy and tolerability of aceklofenak in the treatment of patients with ankylosing spondylitis: a multicentre controlled clinical trial. J. Rheumatol. 1996; 23: 1200-06.
19. Blot L., Marcelis A., Devogelaer J.P., Manicourt D.H.: Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br. J. Pharmacol. 2000; 131: 1413-21.
20. Dingle J.T., Parker M.: NSAID stimulation of human cartilage matrix synthesis: a study of the mechanism of action of aceclofenac. Clin. Drug Invest. 1997; 14: 353-62.
21. Lemmel E.M., Leeb B., de Bast J., Aslanidis S.: Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study. Curr. Med. Res. Opin. 2002; 18: 146-153.
2. EULAR Textbook of Rheumatic Diseases. Bijlsma J.W.J. (red.). BMJ Group, London 2012.
3. Crema A., Crema F., Parnham M.J. et al.: Effect of food on the bioavailability of aceclofenac tablets in healthy volunteers. Eur. J. Clin. Res. 1995; 7: 155-60.
4. Charakterystyka produktu leczniczego aceklofenak.
5. Jordan K.M., Arden N.K., Doherty M. et al.: EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis. Ann. Rheum. Dis. 2003; 62: 1145-55.
6. Batlle-Gualda E., Román Ivorra J., Martin-Mola E. et al.: Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind 6-week randomized controlled trial. Osteoarthritis and Cartilage 2007; 15: 900-8.
7. Diaz C., Rodriguez de la Sera A., Geli C. et al.: Efficacy and tolerability of aceclofenac versus diclofenac in the treatment of knee osteoarthritis: a multicentre study. Eur. J. Rheumatol. Inflamm. 1996; 16: 17-22.
8. Perez Busquier M., Calero E., Rodriguez M. et al.: Comparison of aceclofenac with piroxicam in the treatment of osteoarthritis. Clin. Rheumatol. 1977; 16: 154-59.
9. Kornasoff D., Frerick H., Bowdler J., Montull E.: Aceclofenac is a well-tolerated alternative to naproxen in the treatment of osteoarthritis. Clin. Rheumatol. 1997; 16: 32-38.
10. Schattenkirchner M., Milachowski K.A.: A double-blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute lob back pain. Clin. Rheumatol. 2003; 22: 127-35.
11. Calin A., Murray F.E.: Aceclofenac: side effects and safety. Eur. J. Rheumatol. Inflamm. 1996; 16: 13-6.
12. Huskisson E.C., Irani M., Murray F.: A large prospective open-label, multicentre SAMM study, comparing the safety of aceclofenac with diclofenac in patients with rheumatic disease. Eur. J. Rheumatol. Inflamm. 2000; 17: 1-7.
13. Peris F., Bird H.A., Serni U. et al.: Treatment compliance and safety of aceclofenac versus standard NSAIDs in patients with common arthritic disorders: a meta-analysis. Eur. J. Rheumatol. Inflamm. 1996; 16: 37-45.
14. Yanagawa A., Endo T., Kusakari K. et al.: Endoscopic evaluation of aceclofenac induced gastroduodenal mucosal damage: a double-blind comparison with sodium diclofenac and placebo. Japan J. Rheumatol. 1998; 8: 249-59.
15. Llorente Melero M.J., Tenias Burillo J.M., Caragoza Marcet A.: Comparative incidence of upper gastrointestinal bleeding associated with individual non-steroidal anti-inflammatory drugs. Rev. Esp. Enferm. Dig. 2002; 94: 7-18.
16. Lanas A., Garcýa-Rodrýguez L.A., Arroyo M.T. et al.: Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal antiinflammatory drugs, aspirin and combinations. Gut 2006; 55: 1731-1738.
17. Kornasoff D., Maisenbacher J., Bowdler J., Raber A.: The efficacy and tolerability of aceclofenac compared to indomethacin in patients with rheumatoid arthritis. Rheumatol. Int. 1996; 15: 225-30.
18. Battle-Gualda E., Figueroa M., Ivorra J., Raber A.: The efficacy and tolerability of aceklofenak in the treatment of patients with ankylosing spondylitis: a multicentre controlled clinical trial. J. Rheumatol. 1996; 23: 1200-06.
19. Blot L., Marcelis A., Devogelaer J.P., Manicourt D.H.: Effects of diclofenac, aceclofenac and meloxicam on the metabolism of proteoglycans and hyaluronan in osteoarthritic human cartilage. Br. J. Pharmacol. 2000; 131: 1413-21.
20. Dingle J.T., Parker M.: NSAID stimulation of human cartilage matrix synthesis: a study of the mechanism of action of aceclofenac. Clin. Drug Invest. 1997; 14: 353-62.
21. Lemmel E.M., Leeb B., de Bast J., Aslanidis S.: Patient and physician satisfaction with aceclofenac: results of the European Observational Cohort Study. Curr. Med. Res. Opin. 2002; 18: 146-153.